Sight Sciences, Inc.
SGHTDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
SGHT Earnings Report
EPS Est: $-0.15 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SGHT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BS01 | Phase 2 | Retinitis Pigmentosa | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sight Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Sight Sciences, Inc.'s (SGHT) pipeline across Phase 2. Its lead program is BS01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sight Sciences, Inc.'s next FDA catalyst?→
Sight Sciences, Inc.'s (SGHT) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGHT biotech catalysts?→
Add SGHT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sight Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.